Management of primary intraocular lymphoma.
Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin's lymphoma. PIOL typically presents as a vitritis that is unresponsive to corticosteroid therapy. Diagnosis of PIOL requires pathologic confirmation of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies. The optimal therapy for PIOL has yet to be determined. It is generally believed that PIOL should be treated with a combination of systemic chemotherapy, including high-dose methotrexate and radiotherapy. However, several new developments for PIOL with central nervous system involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation. In addition, intravitreal methotrexate has been successful in the treatment of isolated recurrent ocular disease. This article provides an overview of treatment modalities for initial, recurrent, and relapsed PIOL.
Kim
Stella K
SK
University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, #443, Houston, TX 77030, USA. skim@mdanderson.org
Chan
Chi-Chao
CC
Wallace
Dana J
DJ
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D005134:Eye Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods* / Q000639:trends; D008727:Methotrexate / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods; D012008:Recurrence; D012160:Retina / Q000473:pathology; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D008727:Methotrexate